Novo Nordisk (CPSE:NOVO B) has quietly slipped over the past year, even as its diabetes and obesity franchise keeps growing. That disconnect between share performance and earnings momentum is where ...

Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy ...

Getinge ( ($SE:GETI.B) ) has provided an announcement. Getinge’s Nomination Committee plans to propose seasoned healthcare executive Camilla ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Market sentiment has visibly soured. Year-to-date, the share price is down approximately 52%, and it has declined nearly 60% over a twelve-month period. The stock is trading close to its 52-week low, ...

Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...